Dr. Jacqueline Lui, Managing Director of Eagle IP Limited, gave a talk on “Building a High Value Patent Portfolio” at Shunde, China. Some key features on the talk were reported and published on Shunde Business News at https://s.gdsdss.com/post/2013-06-29/40050879277 and printed on the 28th June 2013 edition of Shunde Business Weekly.
我們過去活動
Recommended Insights
Obviousness: can features from different categories of products be combined to invalidate a design patent?
2025年9月18日Introduction “I have a tank, I have a gun—boom! Tank gun?” Each year the CNIPA releases a list of Top Ten Patent Re-examination and Invalidation Cases. These cases are meant to be guiding cases, showcasing exemplary real-world decisions that clarify certain aspects of the law. Over the next several months we will be highlighting many […]
閱讀更多 >
China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision
2022年9月21日China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
閱讀更多 >
Foreign companies transferring IP out of China: things to know
2018年10月25日Inventions made in China Most foreign companies with R&D sites in China are aware of the fact that inventors having inventions made in China have to obtain permission before they can file patent applications outside of China for these Chinese inventions. It doesn’t matter if the owner of the business is a foreign entity. Patent […]
閱讀更多 >
Compositions Limited by Use: A Cautionary Tale
2022年10月26日Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
閱讀更多 >